Drug Eluting Stent News and Research

RSS

A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.

California researchers receive InHealth grant to evaluate device-intensive procedures

The Institute for Health Technology Studies has awarded a $263,000 grant to a research team at the University of California, Berkeley, to identify and analyze the strategies that hospital systems employ to evaluate and purchase implantable medical devices for cardiac, spinal, and orthopedic procedures.

23 Feb 2011

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).

18 Feb 2011

Boston Scientific fourth quarter net sales decrease 4% to $2.002 billion

Boston Scientific Corporation today announced financial results for the fourth quarter and full year ended December 31, 2010, as well as net sales and earnings per share (EPS) guidance for the full year and first quarter 2011.

2 Feb 2011

Tryton initiates enrollment in Side Branch Stent System study

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first U.S. patient has been enrolled in the pivotal trial to evaluate the Tryton Side Branch Stent System™ for the treatment of coronary artery disease.

27 Jan 2011

Boston Scientific initiates enrollment in comparative Chinese study of PROMUS Element Everolimus-Eluting Stent

Boston Scientific Corporation today announced the beginning of patient enrollment in the PLATINUM China clinical trial, which is designed to evaluate the safety and effectiveness of the Company's PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent compared to the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent in the treatment of patients with a single de novo atherosclerotic lesion.

27 Jan 2011

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2010.

27 Jan 2011

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%.

25 Jan 2011

Boston Scientific completes enrollment in comparison trial of SYNERGY Stent to PROMUS Element Stent

Boston Scientific Corporation today announced the completion of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Company's fourth-generation SYNERGY™ Coronary Stent. The randomized, single-blind, non-inferiority trial will compare the SYNERGY Stent to the PROMUS Element™ Everolimus-Eluting Coronary Stent in patients with a single de novo native coronary artery lesion.

24 Jan 2011

World's first drug eluting bioresorbable vascular scaffold receives CE Mark approval

Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.

10 Jan 2011

Tryton initiates enrollment in Side Branch Stent System trial for coronary artery disease

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first patient has been enrolled in the pivotal trial to evaluate the Tryton Side Branch Stent System™ for the treatment of coronary artery disease.

20 Dec 2010

FFR-guided percutaneous coronary intervention provides cost-saving benefits

St. Jude Medical, Inc., a global medical device company, today announced the publication of results from an economic evaluation of the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial, which confirmed FFR-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease improves patient outcomes and offers cost-saving benefits to the U.S. healthcare system.

17 Dec 2010

ART's stent superior than other bioresorbable stents

Arterial Remodeling Technologies disclosed today new data related to its bioresorbable stent platform—additional data that further validates the Company's innovative approach to simultaneously balance biocompatibility, biomechanics and bioresorption within a bioresorbable PLA (polylactic acid) stent.

8 Dec 2010

FDA approves IDE application to initiate Tryton Side Branch Stent System for coronary artery disease

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced U.S. Food and Drug Administration (FDA) conditional approval for an Investigational Device Exemption (IDE) application to initiate the pivotal trial to evaluate the Tryton Side Branch Stent System for the treatment of coronary artery disease.

2 Dec 2010

Micell initiates enrollment in DESSOLVE I clinical trial of MiStent DES

Micell Technologies,™ Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStent™ Drug Eluting Coronary Stent System (MiStent DES).

29 Nov 2010

Angiotech reports $59.0 million total revenue for third quarter 2010

Angiotech Pharmaceuticals, Inc. today announced that it had released its financial results for the third quarter ended September 30, 2010.

9 Nov 2010

Novel drug-coated balloon technology adopted in niche applications across Europe: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, novel drug-coated balloon technology is being adopted in niche applications throughout Europe. This market will continue to grow as physicians increasingly use the technology in cases where other devices may not be suitable.

4 Nov 2010

Tryton Side Branch Stent System offers new treatment strategy for atherosclerotic lesions

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced interim six-month results from the company's E-Tryton registry evaluating the TRYTON Side Branch Stent System at 15 European sites.

30 Oct 2010

Dual antiplatelet therapy study expanded into Australia and New Zealand

The Harvard Clinical Research Institute (HCRI) announced today that the DAPT Study has expanded into Australia and New Zealand. Professor Ian Meredith, MBBS, Ph.D., interventional cardiologist at MonashHeart in Melbourne, Australia and National Coordinating Investigator for the DAPT Study in Australia, was the first Pacific Rim investigator to enroll patients into the study.

26 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of currency was 0.8%. Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.

19 Oct 2010

Drug Eluting Stent News and Research

Further Reading

California researchers receive InHealth grant to evaluate device-intensive procedures

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Boston Scientific fourth quarter net sales decrease 4% to $2.002 billion

Tryton initiates enrollment in Side Branch Stent System study

Boston Scientific initiates enrollment in comparative Chinese study of PROMUS Element Everolimus-Eluting Stent

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Boston Scientific completes enrollment in comparison trial of SYNERGY Stent to PROMUS Element Stent

World's first drug eluting bioresorbable vascular scaffold receives CE Mark approval

Tryton initiates enrollment in Side Branch Stent System trial for coronary artery disease

FFR-guided percutaneous coronary intervention provides cost-saving benefits

ART's stent superior than other bioresorbable stents

FDA approves IDE application to initiate Tryton Side Branch Stent System for coronary artery disease

Micell initiates enrollment in DESSOLVE I clinical trial of MiStent DES

Angiotech reports $59.0 million total revenue for third quarter 2010

Novel drug-coated balloon technology adopted in niche applications across Europe: MRG

Tryton Side Branch Stent System offers new treatment strategy for atherosclerotic lesions

Dual antiplatelet therapy study expanded into Australia and New Zealand

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News